HR Execs on the Move

Be Biopharma

www.be.bio

 
Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.be.bio
  • One Kendall Square Building 200
    Cambridge, MS USA 02139
  • Phone: N/A

Executives

Name Title Contact Details
Angus Smith
 Chief Financial Officer Profile
David Steinberg
 Co-founder and Chief Executive Officer Profile
Brad Hartman
 Chief People Officer Profile

Similar Companies

Soundbite Medical Solutions

SoundBite Medical is a medical devices company that began operations in May 2015, with its R&D facilities in Sherbrooke and commercialization headquarters in Montreal, Quebec. The Company is developing and commercializing proprietary wire-based device and generator console that delivers safe shockwave energy within the cardiovascular system to treat chronic total occlusions.

454 Life Sciences, a Roche company

454 Life Sciences' system enables one individual to prepare and sequence an entire genome after performing a single sample preparation, irrespective of the size of the genome being studied. The hallmark of 454 Life Sciences' technology is the

Chiropractors Buying Group

Chiropractors Buying Group is a Troy, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Anixa Biosciences

Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.